These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30735705)

  • 1. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Guo T; Zhao L; Zhang Y; Liu G; Yao Y; Li H
    Immunol Lett; 2016 Dec; 180():39-45. PubMed ID: 27816480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
    Wen B; Zhao L; Wang Y; Qiu C; Xu Z; Huang K; Zhu H; Li Z; Li H
    Prep Biochem Biotechnol; 2020; 50(3):252-259. PubMed ID: 31799894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties.
    Xi X; Sun W; Li H; Fan Q; Zhang X; Sun F
    Protein Expr Purif; 2021 Aug; 184():105888. PubMed ID: 33857600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
    Zhu L; Zhao L; Wu M; Chen Z; Li H
    Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
    Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high affinity nanobody against endothelin receptor type B: a new approach to the treatment of melanoma.
    Ji L; Dong C; Fan R; Qi S
    Mol Biol Rep; 2020 Mar; 47(3):2137-2147. PubMed ID: 32080807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
    Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
    Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
    [No Abstract]   [Full Text] [Related]  

  • 17. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.
    Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P
    BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
    Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
    Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
    Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ
    MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.